Enhertu Wins NICE Backing for HER2-Low Breast Cancer After 2024 Rejection
England and Wales' drug value assessor now deems AstraZeneca and Daiichi Sankyo's antibody drug conjugate cost-effective for NHS use in advanced HER2-low breast cancer.
AstraZeneca and Daiichi Sankyo's Enhertu has finally secured a positive recommendation from NICE, the cost-effectiveness watchdog for England and Wales, for use in HER2-low advanced breast cancer. The decision reverses a 2024 rebuff, when the agency had initially declined to back the drug on value grounds.
The antibody drug conjugate targets a specific patient population whose tumors show low levels of HER2 expression, a group that historically had limited targeted treatment options. NICE's change of heart came after a fresh assessment determined that the therapy meets the NHS's cost-effectiveness threshold, clearing the way for routine funding.
This marks a significant win for the drugmakers, who have been pushing to expand Enhertu's reach beyond its earlier approvals in HER2-positive cancers. The approval underscores the growing role of antibody drug conjugates in precision oncology, though the source does not detail specific clinical or financial figures behind the decision.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.